PRESS RELEASE published on 01/24/2024 at 13:00, 2 years 5 months ago PHBI - Pharmagreen Signs Supply Contract and Trade Marked Name Use of SierraSil(R) in Its’ Nutraceutical Formulations Pharmagreen Biotech, Inc., (OTC PINK:PHBI) signed a supply agreement with SierraSil® Health Inc., allowing the incorporation of SierraSil® minerals into its MaxGenomic® formulations. This agreement aims to promote joint tissue detoxification and aid DNA repair with the use of beta-glucans, polysaccharides, and minerals. Pharmagreen is also preparing to launch new gummy products and a pre-workout one-shot formula, all sugar-free and designed to promote wellness. The company's goal is to achieve positive cash flow by year-end and continue developing innovative nutraceutical products. Pharmagreen Biotech Inc SierraSil Minerals MaxGenomic Formulations Nutraceutical Products Wellness Benefits
Published on 07/09/2026 at 13:00, 4 minutes ago Evergold Mobilizes Drill to Golden Lion and Completes MobileMT Airborne Geophysical Survey, Toodoggone District, Northern BC
Published on 07/09/2026 at 12:30, 34 minutes ago Relevant Gold Launches Fully Funded 2026 Drill Program and Receives Five-Year BLM Expanded Exploration Permit at Bradley Peak
Published on 07/09/2026 at 10:00, 3 hours 4 minutes ago GMV Minerals Announces Completion of 16 Diamond Drill Holes on the Mexican Hat Gold Project in SE Arizona - Drill Assays Pending with ~1500 Samples Submitted to Date
Published on 07/09/2026 at 09:35, 3 hours 29 minutes ago Haier Europe Appoints Stagwell (STGW) as Creative Agency for the Haier Brand, Following Ingenuity+ Pitch Process
Published on 07/09/2026 at 09:01, 4 hours 3 minutes ago Apex Critical Metals Announces Listing of Common Shares on Euronext Access Paris
Published on 07/09/2026 at 12:35, 28 minutes ago Cognizant to scale to 5,000 Frontier Certified Engineers and 10,000 Frontier Business Operators
Published on 07/09/2026 at 12:30, 34 minutes ago Immunic to Participate in Investor Conferences in July
Published on 07/09/2026 at 12:16, 47 minutes ago Phase III GRAPPA trial supports ATLG (Grafalon®) as standard of care in matched unrelated donor stem cell transplantation
Published on 07/09/2026 at 07:30, 5 hours 34 minutes ago Half-year liquidity contract statement June 30, 2026
Published on 07/09/2026 at 07:30, 5 hours 34 minutes ago Half-year liquidity contract statement June 30, 2026
Published on 07/08/2026 at 20:00, 17 hours 4 minutes ago ALTAREA - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL